TY  - BOOK
AU  - Mete, Mihriye
TI  - Treatment for anxiety: Mindfulness meditation versus escitalopram (TAME): Design of a randomized, controlled non-inferiority trial
SN  - 1551-7144
PY  - 2020///
KW  - *Anxiety Disorders/th [Therapy]
KW  - *Citalopram/tu [Therapeutic Use]
KW  - *Meditation/mt [Methods]
KW  - *Mindfulness/mt [Methods]
KW  - *Serotonin Uptake Inhibitors/tu [Therapeutic Use]
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Citalopram/ad [Administration & Dosage]
KW  - Citalopram/ae [Adverse Effects]
KW  - Equivalence Trials as Topic
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Research Design
KW  - Serotonin Uptake Inhibitors/ad [Administration & Dosage]
KW  - Serotonin Uptake Inhibitors/ae [Adverse Effects]
KW  - Severity of Illness Index
KW  - Young Adult
KW  - MedStar Health Research Institute
KW  - Journal Article
N2  - Anxiety disorders (generalized anxiety disorder, social anxiety disorder, panic disorder, and agoraphobia) are common, distressing, and impairing. While pharmacotherapy and psychotherapy are first-line treatment strategies for anxiety disorders, many patients are reluctant to take psychiatric medication, and many prefer to avoid any kind of mental health treatment due to stigma or distrust of traditional medical care. We present the trial protocol for the first study comparing first-line medication treatment with Mindfulness-Based Stress Reduction (MBSR), a popular mindfulness meditation training program, for the treatment of anxiety disorders. We will use a non-inferiority, comparative effectiveness trial design, in which individuals with diagnosed anxiety disorders will be randomized to either pharmacotherapy with escitalopram or MBSR for 8weeks of treatment. Treatment outcome will be based on gold standard symptom severity measures assessed by trained independent evaluators blind to treatment allocation. Secondary outcomes will include key symptom and function measures, as well as tolerability and satisfaction with treatment. Findings will provide crucial information to inform decision making about the relative benefits of MBSR versus a first line medication for anxiety disorders by patients, medical care providers, healthcare insurers and other stakeholders. Copyright (c) 2020. Published by Elsevier Inc
UR  - https://dx.doi.org/10.1016/j.cct.2020.105965
ER  -